

SAMPLE DIRECT IMMUNOFLUORESCENCE REPORT

DIAGNOSIS:

ABC Hospital (WA) A08-04321 (Block A1)

Skin, right leg, biopsy: **Consistent with Henoch-Schönlein purpura** by direct immunofluorescence studies (please see comments).

COMMENTS:

Within the dermal vessels are found granular deposits of IgA and C3 (see image, below, right). This suggests the diagnosis of vasculitis, and further raises the question of the diagnosis of Henoch Schönlein vasculitis, given the presence of IgA as the exclusive immunoglobulin. Granular deposits of IgA in dermal vessels have also been described in other conditions, e.g., Berger's disease, and therefore clinical correlation is recommended. REFERENCE: Van Hale HM et al. Journal of American Academy of Dermatology 15:667, 1986.

MATERIAL RECEIVED

A1 = A08-04321, 1 wet specimen

CLIENT REQUEST / CLINICAL HISTORY


Skin IF (Direct)

GROSS DESCRIPTION

Received in Michel's transport media (pH = 6.51) from ABC Hospital (WA) (Dr. Pathologist MD) is a single punch biopsy of skin measuring 3 x 3 x 3 mm.

IMMUNOFLUORESCENCE FINDINGS

The specimen is washed, embedded in OCT media, and snap-frozen in liquid nitrogen cooled isopentane. Frozen sections are cut and incubated with a panel of FITC-conjugated antibodies and localized via direct fluorescence. Positive and negative control slides are reviewed for each test and found to be satisfactory. Results are as indicated in the table below.



Block A08-04321 (Surgery Date: 06/30/2008) - Skin, right leg (PP20080XXXX A1)

Antibodies To	Result
Complement (C3)	Negative
IgA	3+ granular within superficial vessels
IgG	Negative
IgM	Negative

• Electronically signed 07/04/2008: Allen M. Gown, M.D., Medical Director & Chief Pathologist

Per CMS regulations, the pathologist's signature above indicates that this case has been reviewed and the diagnosis made or confirmed by said pathologist.

NOTE: Some of the tests reported here may have been developed and performance characteristics determined by PhenoPath Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. PhenoPath Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.